Brain tumours: Classification and genes

Neurology in Practice

Volumn 75, Issue 2, 2004, Pages

  Collins, V Peter ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ASTROCYTOMA; BASAL CELL NEVUS SYNDROME; CANCER GRADING; CELL CYCLE; CLINICAL FEATURE; COLON POLYPOSIS; COWDEN SYNDROME; EPENDYMOMA; FAMILIAL CANCER; GENE LOCUS; GENE LOSS; GENETIC ANALYSIS; HUMAN; MEDULLOBLASTOMA; MENINGIOMA; NEUROFIBROMATOSIS; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SURGICAL TECHNIQUE; TUMOR CLASSIFICATION; TURCOT SYNDROME; BRAIN TUMOR; CANCER INCIDENCE; CHROMOSOME ABERRATION; GENETIC DISORDER; HISTOPATHOLOGY; IMMUNOCYTOCHEMISTRY; NONHUMAN; WORLD HEALTH ORGANIZATION;

KI 67 ANTIGEN; MERLIN;

EID: 2442642550     PISSN: 14737086     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2004.040337     Document Type: Review

References (121)

1. Kleihues P, Cavenee WK, eds. World Health Organization classification of tumours: Vol. 1. Pathology and genetics of tumours of the nervous system. Lyon: IARC Press, 2000.
2. Bailey P, Cushing H. A classification of tumours of the glioma group on a histogenetic basis with a correlated study of prognosis. Philadelphia: JB Lippincott, 1926.
3. Davis RL, Onda K, Shubuya M, et al. Proliferation markers in gliomas: a comparison of BUDR, KI-67, and MIB-1. J Neurooncol 1995;24:9-12.
4. Williams GH, Romanowski P, Morris L, et al. Improved cervical smear assessment using antibodies against proteins that regulate DNA replication. Proc Natl Acad Sci USA 1998;95:14932-7.
5. Listernick R, Charrow J, Gutmann DH. Intracranial gliomas in neurofibromatosis type 1. Am J Med Genet 1999;89:38-44.
6. Alshail E, Rutka JT, Becker LE, et al. Optic chiasmatic-hypothalamic glioma. Brain Pathol 1997;7:799-806.
7. Jenkins RB, Kimmel DW, Moertel CA, et al. A cytogenetic study of 53 human gliomas. Cancer Genet Cytogenet 1989;39:253-79.
8. Bigner SH, McLendon RE, Fuchs H, et al. Chromosomal characteristics of childhood brain tumors. Cancer Genet Cytogenet 1997;97:125-34.
9. Zattara-Cannoni H, Gambarelli D, Lena G, et al. Are juvenile pilocytic astrocytomas benign tumors? A cytogenetic study in 24 cases. Cancer Genet Cytogenet 1998;104:157-60.
10. Sanoudou D, Tingby O, Ferguson-Smith MA, et al. Analysis of pilocytic astrocytoma by comparative genomic hybridization. Br J Cancer 2000;82:1218-22.
11. James CD, He J, Carlbom E, et al. Loss of genetic information in central nervous system tumors common to children and young adults. Genes Chromosom Cancer 1990;2:94-102.
12. Gutmann DH, Donahoe J, Brown T, et al. Loss of neurofibromatosis 1 (NF1) gene expression in NF1-associated pilocytic astrocytomas. Neuropathol Appl Neurobiol 2000;26:361-7.
13. Kluwe L, Hagel C, Tatagiba M, et al. Loss of NF1 alleles distinguish sporadic from NF1-associated pilocytic astrocytomas. J Neuropathol Exp Neurol 2001;60:917-20.
14. Patt S, Gries H, Giraldo M, et al. p53 gene mutations in human astrocytic brain tumors including pilocytic astrocytomas. Human Pathology 1996;27:586-9.
15. Phelan CM, Liu L, Ruttledge MH, et al. Chromosome 17 abnormalities and lack of TP53 mutations in paediatric central nervous system tumours. Hum Genet 1995;96:684-90.
16. Uhlmann K, Rohde K, Zeller C, et al. Distinct methylation profiles of glioma subtypes. Int J Cancer 2003;106:52-9.
17. Gonzalez-Gomez P, Bello MJ, Lomas J, et al. Epigenetic changes in pilocytic astrocytomas and medulloblastomas. Int J Mol Med 2003;11:655-60.
18. Bijlsma EK, Voesten AM, Bijleveld EH, et al. Molecular analysis of genetic changes in ependymomas. Genes Chromosomes Cancer 1995;13:272-7.
19. Ebert C, von Haken M, Meyer-Puttlitz B, et al. Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas. Am J Pathol 1999;155:627-32.
20. Kraus JA, de Millas W, Sorensen N, et al. Indications for a tumor suppressor gene at 22q11 involved in the pathogenesis of ependymal tumors and distinct from hSNF5/INI1. Acta Neuropathol (Berl) 2001;102:69-74.
21. Lamszus K, Lachenmayer L, Heinemann U, et al. Molecular genetic alterations on chromosomes 11 and 22 in ependymomas. Int J Cancer 2001;91:803-8.
22. von Haken MS, White EC, Daneshvar-Shyesther L, et al. Molecular genetic analysis of chromosome arm 17p and chromosome arm 22q DNA sequences in sporadic pediatric ependymomas. Genes Chromosomes Cancer 1996;17:37-44.
23. Alonso ME, Bello MJ, Arjona D, et al. Analysis of the NF2 gene in oligodendrogliomas and ependymomas. Cancer Genet Cytogenet 2002;134:1-5.
24. Urioste M, Martinez-Ramirez A, Cigudosa JC, et al. Complex cytogenetic abnormalities including telomeric associations and MEN1 mutation in a pediatric ependymoma. Cancer Genet Cytogenet 2002;138:107-10.
25. Nozaki M, Tada M, Matsumoto R, et al. Rare occurrence of inactivating p53 gene mutations in primary non-astrocytic tumors of the central nervous system: reappraisal by yeast functional assay. Acta Neuropathol (Berl) 1998;95:291-6.
26. Ohgaki H, Eibl RH, Wiestler OD, et al. p53 mutations in nonastrocytic human brain tumors. Cancer Res 1991;51:6202-5.
27. Burger PC, Yu IT, Tihan T, et al. Atypical teratoid/rhabdoid tumor of the central nervous system: a highly malignant tumor of infancy and childhood frequently mistaken for medulloblastoma: a pediatric oncology group study. Am J Surg Pathol 1998;22:1083-92.
28. Siegel JA, Rorke LB, Emanuel BS. Monosomy 22 in rhabdoid or atypical teratoid tumors of the brain. N Engl J Med 1989;321:906.
29. Bigner SH, Mark J, Friedman HS, et al. Structural chromosomal abnormalities in human medulloblastoma. Cancer Genet Cytogenet 1988;30:91-101.
30. Biegel JA, Burk CD, Barr FG, et al. Evidence for a 17p tumor related locus distinct from p53 in pediatric primitive neuroectodermal tumors. Cancer Res 1992;52:3391-5.
31. Reardon DA, Michalkiewicz E, Bayett JM, et al. Extensive genomic abnormalities in childhood medulloblastoma by comparative genomic hybridization. Cancer Res 1997;57:4042-7.
32. Bayani J, Zielenska M, Marrano P, et al. Molecular cytogenetic analysis of medulloblastomas and supratentorial primitive neuroectodermal tumors by using conventional banding, comparative genomic hybridization, and spectral karyotyping. J Neurosurg 2000;93:437-48.
33. Michiels EM, Weiss MM, Hoovers JM, et al. Genetic alterations in childhood medulloblastoma analyzed by comparative genomic hybridization. J Pediatr Hematol Oncol 2002;24:205-10.
34. Gilbertson R, Hernan R, Pietsch T, et al. Novel ERBB4 juxtamembrane splice variants are frequently expressed in childhood medulloblastoma. Genes Chromosomes Cancer 2001;31:288-94.
35. Vorechovsky I, Tingby O, Hartman M, et al. Somatic mutations in the human homologue of Drosophila patched in primitive neuroectodermal tumours. Oncogene 1997;15:361-6.
36. Pietsch T, Waha A, Koch A, et al. Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of Drosophila patched. Cancer Res 1997;57:2085-8.
37. Koch A, Waha A, Tonn JC, et al. Somatic mutations of WNT/wingless signaling pathway components in primitive neuroectodermal tumors. Int J Cancer 2001;93:445-9.
38. Dahmen RP, Koch A, Denkhaus D, et al. Deletions of AXIN1, a component of the WNT/wingless pathway, in sporadic medulloblastomas. Cancer Res 2001;61:7039-43.
39. Reifenberger J, Wolter M, Weber RG, et al. Missense mutations in SMOH in sparadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 1998;58:1798-803.
40. Taylor MD, Liu L, Raffel C, et al. Mutations in SUFU predispose to medulloblastoma. Nat Genet 2002;31:306-10.
41. Herms J, Neidt I, Luscher B, et al. C-MYC expression in medulloblastoma and its prognostic value. Int J Cancer 2000;89:395-402.
42. Grotzer MA, Hogarty MD, Janss AJ, et al. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin Cancer Res 2001;7:2425-33.
43. MacDonald TJ, Brown KM, LaFleur B, et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 2001;29:143-52.
44. Gilbertson RJ, Clifford SC. PDGFRB is overexpressed in metastatic medulloblastoma. Nat Genet 2003;35:197-8.
45. Biernat W, Tohma Y, Yonekawa Y, et al. Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Acta Neuropathol (Berl) 1997;94:303-9.
46. von Deimling A, von Ammon K, Schoenfeld D, et al. Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathology 1993;3:19-26.
47. James CD, Carlbom E, Dumanski JP, et al. Clonal genomic alterations in glioma malignancy stages. Cancer Res 1988;48:5546-51.
48. Reifenberger G, Ichimura K, Reifenberger J, et al. Refined mapping of 12q3-q15 amplicons in human malignant gliomas suggests CDK4/SAS ana MDM2 as independent amplification targets. Cancer Res 1996;56:5141-5.
49. Ichimura K, Bolin MB, Goike HM, et al. Deregulation of the p14ARF/ MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res 2000;60:417-24.
50. McCormack BM, Miller DC, Budzilovich GN, et al. Treatment and survival of low-grade astrocytoma in adults - 1977-1988. Neurosurgery 1992;31:636-42; discussion 642.
51. Simpson JR, Horton J, Scott C, et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of mree consecutive radiation therapy oncology group (RTOG) clinical trials. Int J Radiation Oncol Biol Physics 1993;26:239-44.
52. Kimmel DW, O'Fallon JR, Scheithauer BW, et al. Prognostic value of cytogenetic analysis in human cerebral astrocytomas. Ann Neurol 1992;31:534-42.
53. Weber RG, Sabel M, Reifenberger J, et al. Characterization of genomic alterations associated with gliomo progression by comparative genomic hybridization. Oncogene 1996;13:983-94.
54. Rasheed BK, McLendon RE, Herndon JE, et al. Alterations of the TP53 gene in human gliomas. Cancer Res 1994;54:1324-30.
55. James CD, Carlbom E, Nordenskjold M, et al. Mitotic recombination of chromosome 17 in astrocytomas. Proc Ntl Acad Sci USA 1989;86:2858-62.
56. Alonso ME, Bello MJ, Lomas J, et al. Absence of mutation of the p73 gene in astrocytic neoplasms. Int J Oncol 2001;19:609-12.
57. Huang H, Colella S, Kurrer M, et al. Gene expression profiling of low-grade diffuse astrocytomas by cDNA arrays. Cancer Res 2000;60:6868-74.
58. Westermark B, Carlhendrik H, Nister M. Platelet-derived growth factor in human glioma. Glia 1995;15:257-263.
59. Ichimura K, Schmidt EE, Goike HM, et al. Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 1996;13:1065-72.
60. Hoang-Xuan K, Merel P, Vega F, et al. Analysis of the NF2 tumor-suppressor gene and of chromosome 22 deletions in gliomas. Int J Cancer 1995;60:478-81.
61. Ino Y, Silver JS, Blazejewski L, et al. Common regions of deletion on chromosome 22q12.3-q13.1 and 22q13.2 in human astrocytomas appear related to malignancy grade. J Neuropathol Exp Neurol 1999;58:881-5.
62. Miyakawa A, Ichimura K, Schmidt E, et al. Multiple deleted regions on the long arm of chromosome 6 in astrocytic tumours. Br J Cancer 2000;82:543-9.
63. Reifenberger G, Liu L, Ichimura K, et al. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993;53:2736-9.
64. Reifenberger G, Reifenberger J, Ichimura K, et al. Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res 1994;54:4299-303.
65. Reifenberger G, Reifenberger J, Ichimura K, et al. Amplification at 12q13-14 in human malignant gliomas is frequently accompanied by loss of heterozygosity at loci proximal and distal ta the amplification site. Cancer Res 1995;55:731-4.
66. Ekstrand AJ, James CD, Cavenee WK, et al. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 1991;51:2164-72.
67. Costello JF, Plass C, Cavenee WK. Aberrant methylation of genes in low-grade astrocytomas. Brain Tumor Pathol 2000;17:49-56.
68. Watanabe K, Sato K, Biernat W, et al. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res 1997;3:523-30.
69. Reifenberger J, Ring GU, Gies U, et al. Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J Neuropathol Expt Neurol 1996;55:822-31.
70. Lowe SW, Sherr CJ. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet Dev 2003;13:77-83.
71. Roth J, Dobbelstein M, Freedman DA, et al. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. Embo J 1998;17:554-64.
72. Wang JY, Knudsen ES, Welch PJ. The retinoblastoma tumor suppressor protein. Adv Cancer Res 1994;64:25-85.
73. Serrano M, Hannon GJ, Beach D, A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-7.
74. Steck PA, Pershouse MA, Josser SA, et al. Identification of a candidate tumour suppressor gene, MAWC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Genetics 1997;15:356-62.
75. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-7.
76. Ichimura K, Bondesson-Bolin M, Goike HM, et al. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1/S transition control abnormalities. Cancer Res 2000;60:417-25.
77. Schmidt E, Ichimura K, Goike HM, et al. Mutational profile of the PTEN gene in primary human astrocytic tumors and xenografts. J Neuropathol Expt Neurol 1999;58:1170-83.
78. Furnari FB, Huang HJ, Cavenee WK. The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Res 1998;58:5002-8.
79. Myers MP, Stolarov JP, Eng C, et al. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Ntl Acad Sci USA 1997;94:9052-7.
80. Myers MP, Pass I, Batty IH, et al. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci USA 1998;95:13513-8.
81. Zundel W, Schindler C, Haas-Kogan D, et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 2000;14:391-6.
82. Knobbe CB, Reifenberger G, Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3′-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol 2003;13:507-18.
83. Sonoda Y, Ozawa T, Hirose Y, et al. Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. Cancer Res 2001;61:4956-60.
84. Humphrey PA, Wong AJ, Vogelstein B, et al. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci USA 1990;87:4207-11.
85. Wong AJ, Ruppert JM, Bigner SH, et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 1992;89:2965-9.
86. Sugawa N, Ekstrand AJ, James CD, et al. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA 1990;87:8602-6.
87. Nishikawa R, Ji XD, Harmon RC, et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 1994;91:7727-31.
88. Ekstrand AJ, Longo N, Hamid ML, et al. Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene 1994;9:2313-20.
89. Mischel PS, Cloughesy TF. Targeted molecular therapy of GBM. Brain Pathol 2003;13:52-61.
90. Ekstrand AJ, Sugawa N, James CD, et al. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N-and/or C-terminal tails. Proc Natl Acad Sci USA 1992;89:4309-13.
91. Macdonald DR, Gaspar LE, Cairncross JG. Successful chemotherapy far newly diagnosed aggressive oligodendroglioma. Ann Neurol 1990;27:573-4.
92. Reifenberger J, Reifenberger G, Liu L, et al. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 1994;145:1175-90.
93. Reifenberger G, Louis DN. Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 2003;62:111-26.
94. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473-9.
95. Rausing A, Ybo W, Stenflo J. Intracranial meningioma - a population study of ten years. Acta Neurol Scand 1970;46:102-10.
96. Louis DH, Scheithauer BW, Budka H, et al. Meningiomas. In: Kleihues P, Cavenee WK, eds. World Health Organization classification of tumours: vol. 1, pathology and genetics of tumours of the nervous system. Lyon: IARC Press, 2000.
97. Mark J, Levan G, Mitelman F. Identification by fluorescence of the G chromosome lost in human meningomas. Hereditas 1972;71:163-8.
98. Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate far the neurofibromatosis 2 tumor suppressor. Cell 1993;72:791-800.
99. Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993;363:515-21.
100. Shaw RJ, Paez JG, Curto M, et al. The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev Cell 2001;1:63-72.
101. Lallemand D, Curto M, Saotome I, et al. NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes Dev 2003;17:1090-100.
102. McClatchey AI, Saotome I, Mercer K, et al. Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev 1998;12:1121-33.
103. Kalamarides M, Niwa-Kawakita M, Leblois H, et al. Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev 2002;16:1060-5.
104. Giovannini M, Robanus-Maandag E, van der Valk M, et al. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev 2000;14:1617-30.
105. Weber RG, Bostrom J, Wolter M, et al. Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. Proc Natl Acad Sci USA 1997;94:14719-24.
106. Ozaki S, Nishizaki T, Ito H, et al. Comparative genomic hybridization analysis of genetic alterations associated with malignant progression of meningioma. J Neurooncol 1999;41:167-74.
107. Lamszus K, Kluwe L, Matschke J, et al. Allelic losses at 1p, 9q, 10q, 14q, and 22q in the progression of aggressive meningiomas and undifferentiated meningeal sarcomas. Cancer Genet Cytogenet 1999;110:103-10.
108. Cai DX, James CD, Scheithauer BW, et al. PS6K amplification characterizes a small subset of anaplastic meningiomas. Am J Clin Pathol 2001;115:213-8.
109. Cai DX, Banerjee R, Scheithauer BW, et al. Chromosome 1p and 14q FISH analysis in clinicopathologic subsets of meningioma: diagnostic and prognostic implications. J Neuropathol Exp Neurol 2001;60:628-36.
110. Lindblom A, Ruttledge M, Collins VP, et al. Chromosomal deletions in anaplastic meningiomas suggest multiple regions outside chromosome 22 as important in tumor progression. Int J Cancer 1994;56:354-7.
111. Buschges R, Ichimura K, Weber RG, et al. Allelic gain and amplification on the long arm of chromosome 17 in anaplastic meningiomas. Brain Pathol 2002;12:145-53.
112. Perry A, Banerjee R, Lohse CM, et al. A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas. Brain Pathol 2002;12:183-90.
113. Bostrom J, Meyer-Puttlitz B, Wolter M, et al. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas. Am J Pathol 2001;159:661-9.
114. Li YJ, Sanson M, Hoang-Xuan K, et al. Incidence of germ-line p53 mutations in patients with gliomas. Int J Cancer 1995;64:383-7.
115. Malkin D. Li-Fraumeni Syndrome. In: Vogelstein B, Kinzler KW. The genetic basis of cancer. New York: McGraw-Hill, Health Professions Division, 1998:393-422.
116. Gutmann DH, Collins FS. Neurofibromatosis type 1. In: Vogelstein B, Kinzler KW, eds. The genetic basis of cancer. New York: McGraw-Hill, Health Professions Division, 1998:423-42.
117. Mac Collin M, Gusella J. Neurofibromatosis type 2. In: Vogelstein B, Kinzler KW. The genetic basis of cancer. New York: McGraw-Hill, Health Professions Division, 1998:443-54.
118. Hamilton SR, Liu B, Parsons RE, et al. The molecular basis of Turcot's syndrome. N Engl J Med 1995;332:839-47.
119. Vortmeyer AO, Stavrou T, Selby D, et al. Deletion analysis of the adenomatous polyposis coli and PTCH gene loci in patients with sporadic and nevoid basal cell carcinoma syndrome-associated medulloblastoma. Cancer 1999;85:2662-7.
120. Eng C, Parsons R. Cowden syndrome. In: Vogelstein B, Kinzler KW. The genetic basis of cancer. New York: McGraw-Hill, Health Professions Division, 1998:519-526.
121. Kaufman DK, Kimmel DW, Parisi JE, et al. A familial syndrome with cutaneous malignant melanoma and cerebral astrocytoma. Neurology 1993;43:1728-31.